A federal court in a Florida qui tam lawsuit recently ruled that a plaintiff may bring a False Claims Act anti-retaliation lawsuit against defendants other than his employer. (United States ex rel. Koch v. Gulf Region Radiation Oncology, 3:12cv504/RV-CJK (N.D. Fla. Jan. 30, 2013)).

In 2008, West Florida Medical Center Clinic hired Richard Koch as an administrator/manager. After a series of mergers involving West Florida Medical Center Clinic and Sacred Heart Health System, Mr. Koch eventually became an employee of Gulf Region Radiation Oncology. A couple of years later, in January 2010, Gulf Region fired Mr. Koch, allegedly after he raised concerns that they were defrauding government health care programs.

Mr. Koch subsequently filed a False Claims Act anti-retaliation lawsuit against his employer Gulf Region Radiation Oncology and the two predecessor companies, West Florida Medical Center Clinic and Sacred Heart Health System, which both maintained separate legal entity status.

Sacred Heart and West Florida Medical Center Clinic responded by seeking dismissal, arguing Koch was not their employee so they could not be held liable under the False Claims Act for his firing.

The court determined that the defendants’ defense may have had merit before May 2009. However, at that time, the Fraud Enforcement & Recovery Act of 2009 amended and expanded the False Claims Act’s anti-retaliation provision to reach non-employers. Thus, the court found that because the alleged retaliatory discharge happened after May 2009, Mr. Koch could sue West Florida Medical Center Clinic and Sacred Heart Health System, even though they may not have technically been his employers.

More information for whistleblowers is located at the Nolan Auerbach website.

{ 0 comments }

Vanessa Absher and Lynda Mitchell are nurses that worked for years at the Momence Meadows Nursing Center, a 140-bed skilled nursing facility in Illinois that houses disabled and elderly patients, the majority of which are Medicare and Medicaid beneficiaries.

According to Ms. Absher and Ms. Mitchell’s qui tam lawsuit, a number of residents at the facility received grossly substandard care for which Medicare and Medicaid were billed. They also allege that they were directed to falsify patient and medication records to reflect that care and medication were given; and staffing records, to show minimum staffing levels were reached. They were also told to “rechart” patient records, in order to conceal events that led to the injury, illness, or death of some residents.

The nurses allegedly complained to management about the inadequate care being provided to residents, the failure to provide medications and meals to patients, the appalling condition in which residents were found, and other incidents involving the facility’s employees. They also supposedly complained to their supervisors that the facility failed to comply with federal and state laws governing quality of care.

In response, the facility allegedly subjected Ms. Mitchell to continuous verbal abuse and hostility, and she was told to “shut her mouth” and told she could be terminated if she continued to complain. Ms. Mitchell was terminated three days after one of facility’s residents died. When Ms. Absher learned that Ms. Mitchell was terminated, she felt she had no other reasonable choice but to resign. In response, the facility allegedly tried to prevent other employers from hiring them. In fact, according to the nurses, the facility even fabricated charges against both women with the Illinois Department of Professional Regulation.

Ms. Absher and Mitchell’s exceptional qui tam attorneys tried the case before a jury, and late Friday, the jury returned a verdict in favor of the nurses and the federal government, finding defendants knowingly provided worthless services to the nursing home residents. The total verdict was over $28 million, and their share in this healthcare fraud skilled nursing facility case will be over $7 million.

More information for whistleblowers is located at the Nolan Auerbach website.

{ 0 comments }

After closing out a record year for False Claims Act recoveries, the government announced today that New Jersey based Cooper Health System and Cooper University Hospital has agreed to pay $12.6 million to resolve allegations that it paid illegal kickbacks to health care providers. This settlement is one of the largest recoveries for New Jersey under its state False Claims Act.  It is also one of the largest settlements against a hospital for its involvement in an illegal kickback scheme.

The case was originally filed in 2008 by Dr. Nicholas L. DePace who was a prominent Delaware Valley cardiologist.  According to the whistleblower, millions of dollars were being paid to physicians in order that they would refer patients to the Cooper Health System and Cooper University Hospital for expensive in-patient and cardiac services.   It is Dr. DePace’s allegations that started the investigation by the United States Department of Justice and the New Jersey Attorney General’s Office that led to this recovery.

Nolan Auerbach believes that violations of the Anti-kickback Statute by illegally paying healthcare providers continues to date and remains a basis for False Claims Act liability as this case illustrates.  Taxpayers depend on courageous whistleblowers such as Dr. DePace who have the constitutional fortitude to step up to stop these illegal practices.

More information for whistleblowers is located at the Nolan Auerbach website.

{ 0 comments }

Two former employees of the Momence Meadows Nursing Center (MMNC) filed a qui tam action against the nursing home pursuant to the False Claims Act. The relators claimed, among other things, that the care provided by MMNC was so substandard that it was worthless, thus triggering FCA liability. (DOJ filed a statement of interest backing this use of the FCA.)

MMNC filed a summary judgment motion, arguing that the relators’ claim for worthless services should be dismissed. The nursing home argued that it provided “substandard” services, which should be distinguished from not providing any services at all.

The court disagreed and determined that providing substandard services can sometimes blur the line into providing worthless services. With this decision, the court stressed that defendants cannot sidestep FCA liability by simply arguing that they provided some care, albeit woefully substandard.

More information for whistleblowers is located at the Nolan Auerbach website.

{ 0 comments }

A sales manager at Takeda Pharmaceuticals brought a qui tam action against his employer under the False Claims Act. (United States ex rel. Nathan v. Takeda Pharmaceuticals America Inc., No. 11-2077 (4th Cir. 2013)).

The whistleblower claimed that his employer violated § 3729(a)(1)(A) of the Act by causing false claims to be presented to the government for payment.

However, to trigger liability under the Act, a claim for payment must have actually been submitted to the federal government. In dismissing the whistleblower’s suit, the Fourth Circuit determined that the whistleblower failed to point to any specific reimbursement claims submitted to the Government that related to the company’s alleged off-label marketing of its drugs.

The whistleblower said that Takeda was seeking reimbursement for the costs of prescriptions targeted at off-label use, which are typically not subject to government reimbursement. To prove his claim, the whistleblower utilized statistical evidence and made general allegations that Takeda engaged in a “scheme” to defraud the government. However, the whistleblower failed to point to even one specific reimbursement claim by Takeda.

The court stressed that while the whistleblower’s claim show that a false claim could have been filed, liability under the False Claims Act attaches only to false claims that were actually submitted to the government for reimbursement.

In ruling for Takeda, the court added that general allegations do not identify with particularity any claims that would trigger liability under the Act.

To learn more about whistleblowers and the False Claim Act, visit the Nolan Auerbach website.

{ 0 comments }

Annual Report Recaps Florida’s Lucrative War on Medicaid Fraud

by Nolan and Auerbach on January 8, 2013

Florida Agency for Health Care Administration and the Florida Attorney General just released the State’s annual Medicaid Fraud and Abuse Report, which reveals a solid return on investment for recovery efforts. Medicaid is a big issue in Florida – the fourth largest Medicaid program in the country, serving more than 3.3 million people.

Fighting Medicaid fraud makes good financial sense in the State. According to the report, for every $1 spent in fiscal year 2011- ’12 to prevent fraud and abuse or to recover Medicaid funds due to fraud and abuse, Florida gained $6.80.

While Medicaid’s process to terminate prescribing rights of providers who were prescribing suspicious amounts of pill-mill type drugs is going strong. The State recouped nearly $49.7 million, including $44.2 million in overpayments and $5 million in fines and sanctions. In addition, the Agency’s Bureau of Medicaid Program Integrity collected $74.2 million in Medicaid overpayments and the government’s Third Party Liability Unit recovered $148.1 million.

Recouping money from Medicaid fraud and abuse is clearly an important and much-needed money-making initiative for Florida as well as other states. With the strength of the qui tam provisions of the False Claims Act, the amount recovered should increase each year.

According to the report, citizens made the majority of Medicaid fraud complaints in FY 2011-’12, followed by Medicaid recipient and qui tam complaints.

More information for whistleblowers is located at the Nolan Auerbach website.

{ 0 comments }

Recent amendments to the False Claims Act corrected legislative deficiencies that fraudfeasors had used and abused to drain billions of dollars from the U.S. Treasury. Perhaps most importantly, the amendments modernized the Act’s liability provisions so as to explicitly and fully protect government dollars even when the federal government relies on others to make payment decisions for the federal Government. The need for such legislation was heightened by Allison Engine Co. v. United States ex rel. Sanders, a 2008 U.S. Supreme Court decision that narrowed the Act to only apply to false claims that were potentially reviewable by the “Government itself” and that were “material to the Government’s decision to pay.”

To effectively erase this limiting court decision from the books, Congress drafted a corrective liability amendment so that it applied to all “claims” pending two days before the Supreme Court released its Allison Engine decision. While the congressional intent was clear, circuit courts have struggled with how to retroactively apply the new liability provision.

The problem stems with the language of the retroactivity provision, found in § 4(f)(1) of the Fraud Enforcement and Recovery Act of 2009 (“FERA”). FERA states that the new liability provision applies to “all claims under the False Claims Act” that were pending two days prior to Allison Engine. However, while Congress intended “claims” to mean cases, “claims” is specifically defined in the False Claims Act to mean “demands for payment.” Thus, two circuits–the Ninth and Eleventh Circuits–have held that the new liability provision only applies to “demands for payment” that were pending two days before Allison Engine. Conversely, the Second and Seventh Circuits have held that the provision applies to cases pending two days before Allison Engine.

 Recently, the Sixth Circuit broke the circuit tie when it held that the amendment applies to cases pending two days before Allison Engine. Ironically, the Sixth Circuit waded into these unsettled waters in the very case that catalyzed the False Claims Act amendments, United States ex rel. Sanders v. Allison Engine, which had worked its way back up the appellate pipeline. Of particular note, the Sixth Circuit held that the retroactive application of the new liability provision was not violative of the U.S. Constitution’s Ex Post Facto Clause.

Therefore, while Congress passed FERA to unmuddy the False Claims Act waters, the deepening circuit splits around retroactivity have, once again, stirred up confusion. Given the Supreme Court’s recent track record of limiting the reach of the False Claims Act, fraudsters are surely hoping this confusion generates another trip to the Supreme Court.

More information for whistleblowers is located at the Nolan Auerbach website.

{ 0 comments }

According to Taxpayers Against Fraud (TAF), federal and state False Claims Act cases recovered over $9 billion in civil and related criminal fines in fiscal year 2012. This noteworthy sum was a record and over twice the $4 billion recovered for FY 2012. To put this amount in perspective, from 1986 through fiscal year 2011, case filed under the federal False Claims Act returned $30 billion in civil recoveries to the public fisc.

The tremendous returns in 2012 were largely the result of 30 False Claims Act settlements, of which 28 were initiated by qui tam or whistleblowers. Once again, the lions’ share of dollars was from qui tam actions filed against dishonest health care companies and providers. Specifically, $6.5 billion, or 71% of total recoveries, were attributed to health care qui tam actions.

The four largest were cases involved the following defendants: GlaxoSmithKline ($3 billion), Abbott Laboratories ($1.5 billion), Bank of America ($1 billion), and Merck ($950 million).

More information for whistleblowers is located at the Nolan Auerbach website.

{ 0 comments }

Another Court Refuses to Lowball Successful Relators

by Nolan and Auerbach on October 4, 2012

The False Claims Act sets a range of awards for relator share between 15% and 25% to advance two goals. First, the 15% minimum was devised “in the nature of a ‘finder’s fee’ [in order] to develop incentives for people to bring information forward.” 132 Cong. Rec. H9389 (daily ed. Oct. 7, 1986) (statement of Rep. Berman). That amount is therefore paid “even if that person does nothing more than file the action in federal court.” Id. However, where a Relator’s contributions go beyond the mere filing of a complaint, an award well in excess of the statutory minimum is obligatory.

By offering relators the promise of an increased stake in the outcome of their cases based upon the extent to which they substantially contributed to the prosecution of the action, Congress created an incentive for relators and their counsel to commit time, money and resources needed to litigate aggressively on behalf of the taxpayers.

If the Department of Justice offers less of a relator share percentage than is properly due, the relator has the right to bring the issue before the court. The most recent successful challenge played out in an intervened qui tam action that exposed a residential youth center that was mistreating boys suffering from serious mental health. Ultimately, because of the relators’ actions, the mistreatment stopped and the center returned $6.85 million to the federal and Virginia governments. In assisting the government, the relators provided critical information about the fraud, attended all depositions and hearings, submitted briefs in support of the government, and secured the use of an expert who increased the defendants’ potential liability and encouraged the defendants to settle more quickly. Nonetheless, the government sought to limit the relators’ share to 17% of the recovery.

The court decided that a 20% share was more equitable. In reaching its decision, the court analyzed a number of factors, including the relators’ post-filing contributions. The court also acknowledged the gravity of the disclosure in reaching its decision: the significant safety issue posed to residents of the youth center who were not receiving the care they needed.

Hopefully, this decision sends a strong message to potential whistleblowers…and the Justice Department.

More information for whistleblowers is located at the Nolan Auerbach website.

 

{ 0 comments }

Last week, Nolan Auerbach Partners Marcella Auerbach and Jeb White presented at the Twelfth Annual Taxpayers Against Fraud Education Fund (TAFEF) Conference in Washington, D.C. Mr. White, presenting during the opening session of the conference, provided an overview of the False Claims Act, including an in-depth discussion of the recent legislative amendments. Mr. White was joined by U.S. Department of Justice’s Commercial Litigation Branch Director Daniel Anderson and qui tam attorney Shelley Slade.

Managing Partner Marcella Auerbach moderated a plenary panel discussion on multi-relator issues. Panelists included Assistant United States Attorney Zachary Cuhna, qui tam attorney David Chizewer, and former U.S. Department of Justice Assistant Director Stephen Altman.

This year’s TAFEF Conference was the largest event solely devoted to the False Claims Act. In addition to more than 300 qui tam attorneys, the audience included several attorneys from federal and state governments. Speakers included United States Attorneys, high-ranking Justice Department officials, and leading qui tam practitioners.

More information for whistleblowers is located at the Nolan Auerbach website.

{ 0 comments }

Government Investigators Can File Qui Tam Actions

by Nolan and Auerbach on September 11, 2012

For years, the United States Justice Department has argued that government employees cannot bring qui tam actions under the federal False Claims Act. For support, the Justice Department has maintained that the Act’s public disclosure bar is trigger when the government employees disclose the fraud allegations to themselves, private citizens. Furthermore, because the government employee is required to report fraud as a condition of employment, the employees do not “voluntarily” supply the information to the government, as required by the public disclosure bar’s original source exception.

Courts have almost uniformly rejected this argument. In addition to spotlighting the disconnect with the False Claims Act’s statutory language, the courts have stressed the important role government employee-relators play in ferreting out fraud, particularly when a governmental agency is captured by a corrupt industry.

Recently, the Third Circuit joined the chorus, when it held that government employees can file qui tam actions. Even more noteworthy, the court held that government investigators can file actions based on information they uncover during the course of their employment.

More information for whistleblowers is located at the Nolan & Auerbach, P.A. website.

{ 0 comments }

The False Claims Act qui tam provisions encourage and incentivize individuals to report fraudulent business practices that drain funds from the federal government. Oftentimes, current and former employees of dishonest companies are in the best position to expose such corporate behavior. However, companies regularly seek to silence would-be whistleblowers by requiring departing employees to sign nondisclosure agreements and restrictive severance agreements that ostensibly derail potential qui tam actions. Fortunately, many courts are now invalidating these agreements when they are used to gag qui tam relators.

For example, in an ongoing qui tam case in California, the district court refused to strike evidence, which the relators had copied and moved from their hard drives after quitting their employment with the defendant. While recognizing that such behavior arguably violated their signed non-disclosure agreements, the court stressed that the relators took this action only for the purpose of providing the exhibits to the government and corroborating their claims of alleged fraud on the part of their former employer. The court stressed that there is a “strong public policy in favor of protecting whistleblowers who report fraud against the government. . . . Obviously, the strong public policy would be thwarted if [Defendants] could silence whistleblowers and compel them to be complicit in potentially fraudulent conduct.”

This issue has even percolated up to a federal court of appeals, where the Ninth Circuit stated that public policy merits finding such individuals to be exempt from liability for violation of their nondisclosure agreements. Similarly, an Illinois district court held that a relator was exempt from liability for breach of a confidentiality agreement when he disclosed documents to the government that showed that his employer had engaged in fraudulent healthcare billing practices.

This recent trend in the False Claims Act case law signals that non-disclosure agreements and restrictive severance agreements may not preclude qui tam actions. However, with that being said, other courts have not yet joined this growing chorus. Therefore, potential whistleblowers should seek experienced counsel before throwing caution into the wind by downloading documents from their current or former employers’ servers.

More information for whistleblowers is located at the Nolan & Auerbach, P.A. website.

{ 0 comments }

The False Claims Act includes a so-called “first-to-file bar,” 31 U.S.C. 3730(b)(5), which bars subsequent whistleblowers from recovering a reward. They are barred if their complaint is sufficiently similar to prior complaints. However, because the federal rules require whistleblowers to sufficiently detail the alleged fraud, questions have emerged over whether a deficiently pled complaint can still derail a later-filed complaint. There is a widening split in the courts on this issue.

For years, the qui tam bar and the U.S. Department of Justice have advocated the position embraced by the Sixth Circuit Court of Appeals, in United States ex rel. Walburn v. Lockheed Martin Corp., 431 F.3d 966, 972 (6th Cir. 2005). In Walburn, the Court imposed a heightened pleading requirement on complaints for first-to-file purposes. Such an interpretation strikes the appropriate balance between the first-to-file rule’s twin purposes—to encourage whistleblowers to come forward with allegations of fraud and to prevent copycat actions that do not provide additional material information to the Government. Requiring a complaint to meet the Rule 9(b) standards would ensure the complaint provides the Government sufficient information to pursue an investigation, as well as prevent an overly-broad complaint from barring a more detailed, later-filed complaint.

Recently, however, some courts have gone off track and adopted a reading of the first-to-file bar that undermines the government’s enforcement of the False Claims Act. For example, a few months ago, the D.C. Circuit Court of Appeals, affirming a lower court decision, held that a later-filed qui tam action can be barred even when the first-filed suit failed to sufficiently plead the details of the fraud, as required under Federal Rule of Civil Procedure 9(b). All that matter for the D.C. Circuit was that the earlier-filed barebones suit was still “pending” when the later-filed suit was filed.

The District Court of Massachusetts recently echoed the D.C. Circuit, when it held that an earlier-filed qui tam suit could derail a later-filed qui tam suit, even when the first suit failed to clear Rule 9(b). United States ex rel. Heineman-Guta v. Guidant, Civ. No. 09-11927 (D. Mass. July 5, 2012). According to the court, “The purpose of a qui tam action is to provide the government with sufficient notice that it is the potential victim of a fraud worthy of investigation.”

While this is certainly a worthy goal, it conflicts with the statutory language, which dictates that only a “pending action” triggers the first-to-file bar. Thus, the Sixth Circuit correctly noted that “in order to preclude later-filed qui tam actions, the first-filed qui tam complaint must not itself be jurisdictionally or otherwise barred.” Walburn, 431 F.3d at 972. In short, a first-filed action is not really an “action” unless it satisfies the requisite pleading and jurisdictional requirements.

Moreover, by embracing this wayward reading of the Act, such courts are injecting additional uncertainty into the qui tam practice, discouraging well-pled and well informed qui tam actions. Under either reading of the first-to-file-bar, the import is the same for qui tam practitioners’: expeditious preparation of cases in one key to success.

More information for whistleblowers is located at the Nolan & Auerbach, P.A. website.

{ 0 comments }

When Defendants Quickly Resolve False Claims Act Allegations

by Nolan and Auerbach on August 2, 2012

Typically, False Claims Act qui tam actions take many years to be integrated and resolved. Occasionally the lawsuits move quickly, wrapping up within a year or two after the initial filing. Why is there such a wide time disparity? By and large, these expedited FCA actions involve defendants who are highly motivated to clean the slate of fraud allegations.

Commonly, during corporate mergers or acquisitions, the acquiring entities will seek to resolve pending actions against the acquired companies. For example, in December 2011, Halcyon Healthcare acquired Altus Healthcare & Hospice, Inc. Within months of the acquisition, Halcyon agreed to pay $555,572 to the federal government in settlement of allegations contained in a year-old Medicare fraud qui tam lawsuit filed against Altus. Notably, in announcing the settlement, Halcyon emphasized that the problems pre-dated the acquisition and that all issues had been resolved.

Relatedly, new corporate management will regularly seize the moment to come clean about their predecessors’ past digressions. For example, in recent years, several large pharmaceutical fraud cases have settled within months of new CEOs taking the helm. Once again, the public message was that a “new day” had dawned at the company and that the fraudulent missteps were directed by the old leadership.

More information for whistleblowers is located at the Nolan & Auerbach, P.A. website.

{ 0 comments }

For years, would-be whistleblowers shied away from suing state hospitals under the federal False Claims Act. This timidity was primarily due to a 2000 U.S. Supreme Court decision, which held that state agencies could not be sued by qui tam relators. Recently, however, several circuit court decisions have clarified the reach of this decision, particularly as it applies to state-created corporations, including state-created hospitals.

Most recently, the Fourth Circuit Court of Appeals confronted this issue in a case involving state-created student loan companies. The lower court had blindly applied the Supreme Court ruling and had dismissed the qui tam action with little analysis. The appellate court, however, vacated and remanded the decision and stressed that the court must determine whether the corporations are truly under state control.

The Fourth Circuit joined the Fifth, Ninth, and Tenth Circuits in blessing qui tam actions against state-created entities that, in effect, compete on the private market. Deciding factors include the following:

  1. Will a judgment against the entity be paid by the State?
  2. Does the State appoint the directors or officers of the entity?
  3. Is the entity involved in governmental functions?
  4. Is the entity treated as a state agency under the state law?

The answers to these questions will tend to drive the answer to whether a particular entity is truly a state agency. For many entities, including hospitals affiliated with state universities, the answers open the door to Medicare fraud qui tam actions.

For more information about qui tam law and healthcare fraud, contact Nolan & Auerbach, P.A.

 

 

{ 0 comments }

Claims brought under the FCA must comply with the particularity requirements of the Federal Rule of Civil Procedure Rule 9(b). United States ex rel. Thompson v. Columbia/HCA Healthcare Corp., 125 F.3d 899, 903 (5th Cir. 1997).  Rule 9(b) requires, at a minimum, “that a plaintiff set forth the ‘who, what, when, where, and how’ of the alleged fraud.” Id. While this journalistic formula seems simple enough, the real-world application has led to thousands of published district court opinions, wrestling with the application to the federal False Claims Act.

The problem is that an overly stringent Rule 9(b) pleading standard derails meritorious qui tam actions and subverts the very purpose behind the federal False Claims Act qui tam provisions. The reality is that in the vast majority of qui tam cases, the government does not need the assistance of relators in identifying specific false claims. Moreover, such a requirement would undermine the government’s enforcement efforts, for it would discourage the filing of qui tam suits by relators who would otherwise have both the means and the incentive to expose acts of fraud against the United States.

Fortunately, many circuits have honored the intent behind the False Claims Act qui tam provisions by adopting a looser application of Rule 9(b). For example, in the Fifth Circuit, a relator may survive Rule 9(b) even without claims information “by alleging the particular details of a scheme to submit false claims paired with reliable indicia that lead to a strong inference that claims were actually submitted.” United States ex rel. Grubbs v. Kanneganti, 565 F.3d 180, 190 (5th Cir. 2009).

The lowered Rule 9(b) standards are not a complete pass on providing sufficiently detailed information, however. For example, a district court in the Fifth Circuit recently held that a relator failed to satisfy the Grubbs Rule 9(b) standard, when the relator alleged a healthcare kickback scheme without providing any information about the recipients of the kickbacks. See United States ex rel. Nunnally v. West Calcasieu Cameron Hospital, No. 2:08CV0371 (W.D. La. May 21, 2012).

More information for whistleblowers is located at the Nolan & Auerbach, P.A. website.

{ 0 comments }

For decades, the United States Supreme Court has stressed that the federal False Claims Act is “intended to reach all types of fraud, without qualification, that might result in loss to the Government.” United States v. Neifert-White Co., 390 U.S. 228 (1968). This admonition from the Court is worth repeating, particularly as healthcare fraud schemes have become increasingly complex and defense attorneys have tried to rein in the reach of the False Claims Act.

Fortunately, in 2009, Congress restored and modernized the FCA, echoing once again that the False Claims Act should be used to protect all types of fraud on the government dollar, without qualification.

The resulting FCA has become an even stronger weapon against healthcare fraud. Moreover, not only are the courts largely respecting the congressional intent behind the improved Act, but the Department of Justice seems more willing and able to use the Act against all types of healthcare fraud schemes.

With that being said, even the most complex healthcare fraud schemes are, at their root, instances of defendants overcharging the government or wrongfully retaining government money, property, or benefits. All of these bedrock FCA allegations echo back to very founding of the False Claims Act, when President Lincoln raised concerns that contractors were defrauding the Union Army.

The government recently resolved a False Claims Act qui tam action against St. Jude Medical Inc., in which the company inflated the cost of pacemakers and defibrillators it sold the government.  According to the qui tam complaint, St. Jude actively marketed its pacemakers and defibrillators by touting the generous credits available should a device need to be replaced while covered under warranty. At the same time, St. Jude knew that it failed to give appropriate credits to device buyers in a number of cases where a product was replaced while still under warranty. In short, the company allegedly overcharged the government.

This successful qui tam action is a great reminder that present-day healthcare fraud schemes may include new bells and whistles. However, at the end of the day, they all sound the same old tune of dishonesty and deceit—and the False Claims Act is available to silence the fraud.

For more information about qui tam law and healthcare fraud, contact Nolan & Auerbach, P.A.

{ 0 comments }

Struggling to decipher the False Claims Act’s public disclosure bar, a 2008 district court decision aptly summed up the prevailing sentiment: “The Court sympathizes with anyone litigating under the False Claims Act. Perhaps Congress will elect at some point to give legislative attention to the FCA to resolve some of the still unresolved questions about the Act’s application.” United States ex rel. Montgomery v. St. Edward Mercy Medical Center, 2008 WL 110858 (E.D. Ark. 2008). In 2009 Congress amended the FCA and removed much of the confusion surrounding the much-litigated public disclosure bar.

With no explicit retroactive provision in the 2009 amendments, courts are still wrestling with the old public disclosure bar language.  Undoubtedly, courts have dissected every single word in the old public disclosure bar. In fact, there are over 300+ published and unpublished rulings in well over 150 separate cases concerning the meaning of the “public disclosure” bar. A large percentage of these decisions have marinated on the “based upon” language found in provision.

With the exception of the Fourth Circuit, all of the courts have interpreted “based upon” to mean “substantially similar.” In other words, a qui tam action is “based upon” a public disclosure when the allegations are “substantially similar.” Of particular importance, this interpretation was cemented into the new public disclosure bar when Congress replaced “based upon” with “substantially similar.”

Recently, the Seventh Circuit clarified the “substantially similar” language interpreted into the old public disclosure bar and, by extension, codified into the new public disclosure bar. Specifically, in United States ex rel. Goldberg v. Rush University Medical Center, No. 10-3785 (7th Cir. May 21, 2012), the Court stressed that qui tam allegations are not “substantially similar” to publicly disclosed allegations unless they both disclose a particular fraud by particular defendant.  The Court emphasized that “a very high level of generality is appropriate, because then disclosure of some frauds could end up blocking private challenges to many different kinds of frauds.” Id. at 5.

The Goldberg decision properly encourages insiders to step forward with detailed information. Hopefully the other circuits will embrace this commonsense reading.

For more information about qui tam law and healthcare fraud, contact Nolan & Auerbach, P.A.

{ 0 comments }

The highly influential D.C. Circuit Court of Appeals recently held that courts must hold fairness hearings when a relator challenges the adequacy of a False Claims Act settlement. See United States ex rel. Schwizer v. Océ N.V., No. 11-7030 (D.C. Cir. April 20, 2012). The Court simply applied the explicit statutory language of the Act:

The settlement agreement here falls squarely within § 3730(c)(2)(B): the government reached an agreement with the defendant to “settle the action . . . notwithstanding the objections of the person initiating the action.” In that circumstance, the statute required the district court to “determine, after a hearing, [whether] the proposed settlement [was] fair, adequate, and reasonable under all the circumstances.” 31 U.S.C. § 3730(c)(2)(B)

Id. at 10.

In turn, the D.C. Circuit followed the mandates of Congress and determined that it could not simply tune out the voiced concerns of the relator when it comes to adequacy of a False Claims Act settlement.

As for the constitutional concerns, the D.C. Circuit noted the courts regularly play a role in scrutinizing settlement agreements. For example, in the criminal context, under Federal Rule of Criminal Procedure 48(a), the government can only “dismiss an indictment, information, or complaint” “with leave of the court.” Moreover, the Court noted that in this particular case, the government invoked the court’s supervisory powers by urging the district court to “retain jurisdiction to . . . enforce the terms of the settlement agreement by and between the parties.”

More information for healthcare fraud whistleblowers is located at the Nolan & Auerbach, P.A. website.

{ 0 comments }

The First Circuit has led the change in rejecting the rigid divisions between factual and legal falsity, and express and implied certification, noting that the text of the False Claims Act (FCA) does not make such distinctions.  Specifically, in Hutcheson, the First Circuit declared that such distinctions “may do more to obscure than clarify the issues…” United States ex rel. Hutcheson v. Blackstone Medical, Inc., 647 F.3d 377, 385-86 (1st Cir. 2011). Instead, the First Circuit has taken a broad view of what may constitute “false or fraudulent” statement to avoid “foreclose[ing] FCA liability in situations that Congress intended to fall within the Act’s scope.” Id. at 387 (quoting United States v. Sci. Applications Int’l Corp., 626 F.3d 1257, 1268 (D.C. Cir. 2010)) (internal quotation marks omitted).

Recently, the First Circuit had an opportunity to apply its renewed reading of “false or fraudulent” statements, in United States ex rel. Jones v. Brigham and Women’s Hospital, No. 10-2301 (1st Cir. May 7, 2012). In this NIH grant case, the defendants allegedly violated the False Claims Act by including false statements in a grant application that was submitted to the NIH. Importantly, at least from the defendants’ point of view, the application did not include the supposed false data that formed the basis of their study proposal.

In reversing the lower court’s decision, the First Circuit ruled that the statements in the grant application were still sufficiently “false” to trigger FCA liability. According to the Court, “Although it is true that the allegedly false [ ] data was not itself included in the Application, that fact is not determinative of the false claim allegation. The statute makes it a violation to ‘use . . . a false record or statement to get a false or fraudulent claim paid or approved by the Government.’ 31 U.SC. § 3729(a)(2).”

In a sense, the underlying false data tainted the subsequent statements in the grant application. The court noted, “These statements rel[ied] on the data challenged by [the Relator] as false. In the language of the FCA, they ‘use[d] . . . a false record.’ Thus premised, the statements would not be ‘true, complete and accurate’ as required by the certifications signed” by the Defendants.

The Court stressed that the relator would still need to clear two other FCA elements—materiality and knowledge. However, the “falsity” element was sufficiently pled, even if the allegations did not neatly fit into an “express certification” or “implied certification” box.

More information for whistleblowers is located at the Nolan & Auerbach, P.A. website.

{ 0 comments }